HRTX Heron Therapeutics, Inc.

14.35
+0.15  (1%)
Previous Close 14.20
Open 14.25
Price To book 0.00
Market Cap N/A
Shares 0
Volume 226,515
Short Ratio 0.00
Av. Daily Volume 697,945

Drug Information

Drug catalyst information is displayed when you hover over the stage bar graph.

Phase 2 data released August 2016. Phase 3 trial to be initiated in 2017 with NDA filing in 2018.
HTX-011
Hernia repair
Phase 2 data released August 2016
HTX-011
Bunionectomy
CRL Mar 28 2013. Approved August 10 2016.
APF530 - Sustol
Prevention of acute- and delayed-onset chemotherapy-induced nausea and vomiting (CINV)
PDUFA date November 12, 2017.
CINVANTI (HTX-019)
Prevention of chemotherapy-induced nausea and vomiting (CINV)

Latest News

  1. Heron Therapeutics, Inc. – Value Analysis (NASDAQ:HRTX) : May 12, 2017
  2. Heron Therapeutics, Inc. breached its 50 day moving average in a Bearish Manner : HRTX-US : May 11, 2017
  3. Heron Therapeutics reports 1Q loss
  4. Heron Therapeutics Reports Financial Results for the Three Months Ended March 31, 2017 and Recent Corporate Progress
  5. Heron Therapeutics to Present at the Bank of America Merrill Lynch 2017 Healthcare Conference
  6. Blog Coverage Zogenix Announces Completion of Enrollment for the Phase III Trial in Dravet Syndrome
  7. Heron Therapeutics Appoints Robert E. Hoffman as Chief Financial Officer and Senior Vice President, Finance
  8. Overcoming Opioids: The quest for less addictive drugs
  9. Heron Therapeutics, Inc. breached its 50 day moving average in a Bearish Manner : HRTX-US : April 5, 2017
  10. Heron Therapeutics to Present at the 16th Annual Needham Healthcare Conference
  11. Heron Therapeutics to Present at the Oppenheimer 27th Annual Healthcare Conference
  12. Heron Therapeutics, Inc. breached its 50 day moving average in a Bullish Manner : HRTX-US : March 9, 2017
  13. Heron Therapeutics Inc (HRTX) Sustol To Be Included In Antiemesis Guidelines By NCCN
  14. Heron Therapeutics to Present at the 37th Annual Cowen and Company Healthcare Conference
  15. Heron Therapeutics Announces Inclusion of SUSTOL® (Granisetron) Extended-Release Injection in NCCN® Antiemesis Guidelines
  16. Heron Therapeutics Announces Fourth Quarter and Full Year 2016 Financial Results and Recent Corporate Progress
  17. Acadia Pharmaceuticals Surge Higher Is More Than M&A Rumors
  18. Heron Therapeutics to Present at the Leerink Partners 6th Annual Global Healthcare Conference

SEC Filings

  1. 10-Q - Quarterly report [Sections 13 or 15(d)] 17828570
  2. 8-K - Current report 17828547
  3. DEFA14A - Additional definitive proxy soliciting materials and Rule 14(a)(12) material 17784620
  4. DEF 14A - Other definitive proxy statements 17784578
  5. 8-K - Current report 17778435
  6. PRE 14A - Other preliminary proxy statements 17757049
  7. 8-K - Current report 17733114
  8. 8-K - Current report 17698171
  9. 10-K - Annual report [Section 13 and 15(d), not S-K Item 405] 17633084
  10. 8-K - Current report 17632979